A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Clinical trial NCT02220842 · COMPLETED
Trial details
- NCT number
- NCT02220842
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-18
- Primary completion
- 2020-01-21
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.